Role of anti-Müllerian hormone in predicting premature ovarian insufficiency after pelvic radiotherapy

The authors investigate the role of anti-Müllerian hormone (AMH) as a predictive biomarker for premature ovarian insufficiency (POI) in premenopausal women who have undergone pelvic radiotherapy. Their findings suggest that AMH levels decline more rapidly than follicle-stimulating hormone (FSH) and indicate that minimizing radiation exposure to the ovaries is crucial for preserving ovarian function post-treatment. The study highlights the potential of AMH in assessing ovarian reserve and the risk of POI following radiotherapy.